Status:
NOT_YET_RECRUITING
Piloting 18F-FAPI PET/MRI for Applications in Breast Cancer
Lead Sponsor:
St. Olavs Hospital
Collaborating Sponsors:
Norwegian University of Science and Technology
Conditions:
Breast Neoplasm Female
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Breast cancer is the most common type of cancer in Norwegian women, with 4,224 new cases in 2022. More precise diagnosis are expected to result in more accurate assessment of treatment effect, and to ...
Eligibility Criteria
Inclusion
- Inclusion criteria are accepting to undergo 18F-FAPI PET/MRI examinations and
- diagnosed with local invasive breast cancer,
- scheduled for neoadjuvant therapy as primary treatment,
- has recurrent or new breast cancer, or
- scheduled for neoadjuvant therapy as primary treatment with FDG-PET/CT applied for staging.
Exclusion
- other primary malignancies than breast cancer, renal insufficiency or know allergy towards contrast agents, and MR incompatible implants.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2038
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07180433
Start Date
October 1 2025
End Date
December 31 2038
Last Update
September 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.